Arbutus Biopharma
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Arbutus Biopharma's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 54% to $18,141,000. Profit margin reached -402%. Total operating expenses were $96,244,000.

Profit Margin

Arbutus Biopharma Corporation (NASDAQ:ABUS): Profit margin
2014 15M -38.8M -258.67%
2015 24.87M -61.12M -245.73%
2016 1.5M -384.1M -25606.67%
2017 10.7M -84.4M -788.79%
2018 5.9M -57.1M -967.8%
2019 6.01M -153.72M -2557.36%
2020 6.91M -65.21M -943.17%
2021 10.98M -77.35M -703.96%
2022 39.01M -69.45M -178.01%
2023 18.14M -72.84M -401.57%

ABUS Income Statement (2014 – 2023)

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue
Revenue
18.14M39.01M10.98M6.91M6.01M5.9M10.7M1.5M24.87M15M
Cost of revenue
73.7M1.42M1.75M47.48M57.60M57.9M62.7M61.3M51.50M38.7M
Gross profit
-55.55M37.59M9.23M-40.56M-51.59M-52M-52M-59.8M-26.63M-23.7M
Operating exp.
Research and development
73.7M84.40M65.50M47.48M57.60M57.9M62.7M61.3M51.50M38.7M
Selling and marketing
0000000000
Total operating expenses
96.24M102.24M82.63M64.18M77.35M76.1M80.8M101.8M78.53M47.9M
Operating income
-78.10M-65.45M-73.52M-57.80M-144.07M-89.8M-110.9M-491.6M-102.32M-33M
Other income (expenses), net
5.25M444K-2.72M-5.93M-22.30M6M2.19M-388.8M25.01M-5.40M
Income before tax
-72.84M-65.01M-76.24M-63.74M-166.37M-61.4M-108.7M-489.1M-77.30M-38.7M
Income tax expense
04.44M1.10M1.46M-12.65M-4.3M-24.3M-105M-16.18M100K
Net income
-72.84M-69.45M-77.35M-65.21M-153.72M-57.1M-84.4M-384.1M-61.12M-38.8M
Earnings per share
Basic EPS
-0.44-0.46-0.73-0.86-2.69-1.03-1.54-7.24-1.34-1.8
Diluted EPS
-0.44-0.46-0.73-0.86-2.69-1.03-1.54-7.24-1.34-1.73
Data sourceData sourceData sourceData sourceData sourceData sourceData sourceData sourceData sourceData source